Collagen/Heparin Bi-Affinity Multilayer Modified Collagen Scaffolds for Controlled bFGF Release to Improve Angiogenesis In Vivo

Macromol Biosci. 2018 Nov;18(11):e1800086. doi: 10.1002/mabi.201800086. Epub 2018 Aug 29.

Abstract

Basic fibroblast growth factor (bFGF) is an important protein for wound healing and angiogenesis in tissue engineering, but the lack of a viable delivery system hampers its clinical application. This study aims to maintain the long-term controlled release of bFGF by utilizing a collagen/heparin bi-affinity multilayer delivery system (CHBMDS), which is fabricated by the alternate deposition of negatively charged heparin, positively charged collagen, and CBD-bFGF (a collagen-binding domain [CBD] was fused into the native bFGF) via specific or electrostatic interaction. The results show that CHBMDS not only support localized and prolonged release of CBD-bFGF(over 35 days) but also lead to enhanced angiogenesis (higher density and larger diameter (≈70 µm) of newly formed blood vessels in subcutaneous tissue of SD rat after 5 weeks). This system could act as a versatile approach for bFGF delivery and further improve therapeutic efficacy for injured tissues.

Keywords: angiogenesis; bi-affinity; collagen; controlled release; heparin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Collagen / chemistry*
  • Delayed-Action Preparations / chemistry
  • Delayed-Action Preparations / pharmacokinetics
  • Delayed-Action Preparations / pharmacology
  • Fibroblast Growth Factor 2* / chemistry
  • Fibroblast Growth Factor 2* / pharmacokinetics
  • Fibroblast Growth Factor 2* / pharmacology
  • Heparin / chemistry*
  • Male
  • Neovascularization, Physiologic / drug effects*
  • Rats
  • Rats, Sprague-Dawley
  • Tissue Scaffolds / chemistry*

Substances

  • Delayed-Action Preparations
  • Fibroblast Growth Factor 2
  • Heparin
  • Collagen